Kuros Biosciences AG (CSBTF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Kuros Biosciences AG (CSBTF) trades at $26.99 with AI Score 57/100 (Grade B). Kuros Biosciences AG is a biopharmaceutical company focused on tissue repair and bone regeneration. Market cap: $1.06B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for CSBTF: CSBTF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CSBTF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CSBTF: 1/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Kuros Biosciences AG (CSBTF) Healthcare & Pipeline Overview
Kuros Biosciences AG specializes in developing and commercializing biopharmaceutical products for tissue repair and bone regeneration, with a focus on orthobiologics and sealants. The company's pipeline targets significant unmet needs in orthopedics, spinal surgery, and neurosurgery, positioning it within the competitive biotechnology landscape.
What Is the Investment Thesis for CSBTF?
Kuros Biosciences AG presents a compelling investment thesis based on its innovative product pipeline and strategic focus on tissue repair and bone regeneration. With a market capitalization of $1.06B and a P/E ratio of 563.02, the company demonstrates significant growth potential. Key value drivers include the commercial success of MagnetOs products and the advancement of KUR-111 and KUR-113 through clinical trials. The company's collaboration with Checkmate Pharmaceuticals also adds potential upside. However, investors should be aware of the risks associated with clinical trial outcomes and regulatory approvals. The company's high gross margin of 87.0% indicates pricing power. The beta of 0.63 suggests lower volatility than the market.
Based on FMP financials and quantitative analysis
CSBTF Key Highlights
Market capitalization of $1.06B reflects investor confidence in Kuros Biosciences' growth potential.
- A P/E ratio of 563.02 indicates high expectations for future earnings growth.
- Gross margin of 87.0% demonstrates strong pricing power and efficient cost management.
- Beta of 0.63 suggests lower volatility compared to the broader market.
- The company's focus on tissue repair and bone regeneration addresses a significant market need in orthopedics, spinal surgery, and neurosurgery.
Who Are CSBTF's Competitors?
CSBTF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ASCLF Ascletis Pharma Inc. | $1.30 | +0.00% | $1.36B | 52 |
| CHIZF China Traditional Chinese Medicine Holdings Co. Limited | $0.16 | +0.00% | $821M | 44 |
| CSPHF CStone Pharmaceuticals | $0.70 | +0.00% | $1.12B | 50 |
| MEOBF Mesoblast Limited | $1.89 | +0.00% | $2.45B | 67 |
| NPPNY Nippon Shinyaku Co., Ltd. | $5.61 | +0.00% | $1.51B | 58 |
| CVAC CureVac N.V. | $4.66 | +0.00% | $1.05B | 71 |
| VERV Verve Therapeutics, Inc. | $11.13 | +0.27% | $994M | 71 |
| CLYM Climb Bio, Inc. | $17.02 | -1.85% | $975M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CSBTF's Key Strengths?
Innovative product pipeline targeting unmet clinical needs.
- Strong gross margin indicating pricing power.
- Established presence in key markets (US and EU).
- Strategic partnerships and collaborations.
What Are CSBTF's Weaknesses?
Reliance on successful clinical trial outcomes.
- Dependence on regulatory approvals.
- Limited product diversification.
- OTC market trading may limit liquidity.
What Could Drive CSBTF Stock Higher?
Clinical trial results for KUR-111 in tibial plateau fractures (2027-2028).
- Clinical trial results for KUR-113 in tibial shaft fractures and spinal interbody fusion (2027-2028).
- Regulatory approval and commercial launch of Neuroseal in the EU and US (2026-2027).
- Expansion of MagnetOs product line into new geographic markets.
- Strategic partnerships and collaborations to expand product pipeline.
What Are the Key Risks for CSBTF?
Unfavorable clinical trial results for KUR-111 and KUR-113.
- Delays in regulatory approval for Neuroseal.
- Competition from other biopharmaceutical companies.
- Dependence on successful commercialization of existing products.
- Risks associated with operating in the OTC market.
What Are the Growth Opportunities for CSBTF?
- Expansion of MagnetOs product line: Kuros Biosciences can expand the MagnetOs product line into new geographic markets and applications. The global orthobiologics market is projected to reach $7.9 billion by 2027, providing a significant opportunity for growth. Timeline: Ongoing.
- Advancement of KUR-111 and KUR-113: Successful completion of clinical trials and regulatory approval for KUR-111 and KUR-113 would represent a major growth catalyst for Kuros Biosciences. These products target tibial plateau and tibial shaft fractures, respectively, addressing a significant unmet need in orthopedic surgery. Timeline: 2027-2028.
- Commercialization of Neuroseal: The commercialization of Neuroseal, a synthetic tissue sealant for the prevention of cerebrospinal fluid leakage, represents another growth opportunity for Kuros Biosciences. The market for tissue sealants is growing, driven by increasing demand for minimally invasive surgical procedures. Timeline: 2026-2027.
- Strategic partnerships and collaborations: Kuros Biosciences can pursue strategic partnerships and collaborations to expand its product pipeline and geographic reach. The collaboration with Checkmate Pharmaceuticals for the development of CYT003 demonstrates the company's commitment to this strategy. Timeline: Ongoing.
- Acquisition of complementary technologies: Kuros Biosciences can acquire complementary technologies to strengthen its product portfolio and enhance its competitive position. This could include technologies related to biomaterials, drug delivery, or surgical techniques. Timeline: Opportunistic.
What Threats Does CSBTF Face?
- Competition from other biopharmaceutical companies.
- Changes in regulatory requirements.
- Unfavorable clinical trial results.
- Economic downturn affecting healthcare spending.
What Are CSBTF's Competitive Advantages?
- Proprietary technology and intellectual property.
- Established distribution network in key markets.
- Strong relationships with key opinion leaders.
- Regulatory expertise and experience.
What Does CSBTF Do?
Kuros Biosciences AG, headquartered in Schlieren, Switzerland, is a biopharmaceutical company dedicated to the development and commercialization of innovative products for tissue repair and bone regeneration. The company operates through three segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio. Kuros Biosciences' story began with a vision to address unmet needs in orthopedics, spinal surgery, and neurosurgery through advanced biopharmaceutical solutions. Their lead products, MagnetOs Granules and MagnetOs Putty, are designed for orthopedic, spinal, and dental applications and are available in both the EU and the US. The company's pipeline also includes fibrin/PTH orthobiologics, such as KUR-111, which has completed Phase 2b clinical trials for tibial plateau fractures, and KUR-113, which has completed Phase 2b clinical trials for tibial shaft fractures and is in Phase II trials for spinal interbody fusion. Additionally, Kuros Biosciences is developing Neuroseal EU and US, a synthetic tissue sealant aimed at preventing cerebrospinal fluid leakage following cranial or spinal surgery. Kuros Biosciences also has a collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for oncology treatments. The company's strategic focus on innovation and partnerships positions it for continued growth in the biopharmaceutical sector.
What Products and Services Does CSBTF Offer?
- Develops and commercializes biopharmaceutical products.
- Focuses on tissue repair and bone regeneration.
- Offers orthobiologics pipeline products like MagnetOs Granules and MagnetOs Putty.
- Develops fibrin/PTH orthobiologics such as KUR-111 and KUR-113.
- Creates sealants pipeline products including Neuroseal EU and US.
- Collaborates with other companies for oncology treatments.
How Does CSBTF Make Money?
- Develops and commercializes proprietary biopharmaceutical products.
- Generates revenue through product sales in the US, EU, and internationally.
- Partners with other companies for collaborative development and commercialization.
- Focuses on high-margin products in specialized therapeutic areas.
What Industry Does CSBTF Operate In?
Kuros Biosciences AG operates within the biotechnology industry, which is characterized by rapid innovation and intense competition. The market for tissue repair and bone regeneration is driven by an aging population, increasing demand for minimally invasive surgical procedures, and advancements in biomaterials. Kuros Biosciences competes with other biopharmaceutical companies developing similar products, including ASCLF (Ascentage Pharma Group Corp), CHIZF (Chiesi Farmaceutici SpA), CSPHF (CASI Pharmaceuticals Inc), MEOBF (MeoVaccs), and NPPNY (Nippon Piston Ring Co Ltd). The company's success depends on its ability to develop and commercialize innovative products that address unmet clinical needs and gain regulatory approval.
Who Are CSBTF's Key Customers?
- Hospitals and surgical centers.
- Orthopedic surgeons and neurosurgeons.
- Dental professionals.
- Patients requiring tissue repair and bone regeneration.
Forward Outlook
Wall Street analysts project Kuros Biosciences AG revenue of about $164.2M for fiscal 2026, with EPS near $0.24. The estimate reflects 3 contributing analysts.
Financial Health
Kuros Biosciences AG's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 13.29 places it in the safe zone, indicating low near-term bankruptcy risk.
Key Financial Metrics
Return on equity for Kuros Biosciences AG stands at 2.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.5%, showing how much profit it generates from its asset base. CSBTF trades at a trailing price-to-earnings ratio of 437.69, above the Healthcare sector average of ~23x. Its free cash flow yield is -0.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.96 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.2%, the inverse of the P/E and a quick read on earnings relative to price.
Kuros Biosciences AG (CSBTF) Valuation Context
Valued at $1.06B, CSBTF is classified as a small-cap stock. Relative to its peer group, CSBTF's quantitative score of 57/100 is roughly in line with the peer average of 54/100.
CSBTF Revenue & Earnings Trend
In Q2 2026, CSBTF generated $72.3M in top-line revenue, marking a sequential increase of 9.4%. The company recorded net income of $3.4M, with diluted EPS of $0.09. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company. Across the four most recent quarters, CSBTF averaged $0.01 in diluted EPS.
Company Profile
Kuros Biosciences AG operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Schlieren, CH. The company is led by CEO Christopher T. Fair. CSBTF has traded publicly since 2014.
CSBTF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Kuros Biosciences' future prospects, indicating that key stakeholders believe in the company's potential.
- Community sentiment has shifted positively as recent product developments have sparked interest among investors and healthcare professionals alike.
- The company's innovative approach to regenerative medicine is gaining traction, with heightened discussions around its applications in the market.
- Recent partnerships and collaborations have been perceived favorably, enhancing the company's visibility and credibility in the biotech sector.
Bear Case
- Despite positive developments, some analysts remain cautious due to the inherent risks associated with biotech investments, which can be volatile and unpredictable.
- Community discussions have also highlighted concerns regarding the pace of product approvals, which could affect the company's growth trajectory.
- There are lingering doubts about competition in the regenerative medicine space, with several companies vying for market share, potentially impacting Kuros's positioning.
- Recent market trends indicate a broader bearish sentiment towards biotech stocks, which may weigh on investor enthusiasm for Kuros Biosciences in the near term.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $72M | $3M | $0.09 |
| Q4 2025 | $66M | $4M | $0.10 |
| Q2 2025 | $63M | -$2M | -$0.05 |
| Q4 2024 | $44M | -$4M | -$0.09 |
Based on FMP financials and quantitative analysis
CSBTF Latest News
No recent news available for CSBTF.
CSBTF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CSBTF.
Price Targets
Wall Street price target analysis for CSBTF.
CSBTF MoonshotScore
What does this score mean?
The MoonshotScore rates CSBTF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Christopher T. Fair
CEO
Christopher T. Fair serves as the CEO of Kuros Biosciences AG, leading a team of 122 employees. His background includes extensive experience in the biopharmaceutical industry, with a focus on commercialization and strategic development. Prior to joining Kuros, Mr. Fair held leadership positions at various pharmaceutical companies, where he was responsible for driving revenue growth and expanding market share. He brings a wealth of knowledge in product development, regulatory affairs, and business development to Kuros Biosciences.
Track Record: Under Christopher T. Fair's leadership, Kuros Biosciences has focused on advancing its product pipeline and expanding its commercial presence. Key achievements include the successful commercialization of MagnetOs products and the advancement of KUR-111 and KUR-113 through clinical trials. He has also overseen the company's collaboration with Checkmate Pharmaceuticals, demonstrating his commitment to strategic partnerships.
CSBTF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Kuros Biosciences AG (CSBTF) may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, and investors should exercise caution due to the potential for increased risk and volatility. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and may not be subject to the same level of scrutiny.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in CSBTF.
- Lower liquidity can lead to increased price volatility.
- The OTC Other tier indicates a higher risk profile compared to companies listed on major exchanges.
- Potential for fraud or manipulation is higher on the OTC market.
- Lack of regulatory oversight can make it difficult to assess the company's legitimacy.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's competitive landscape and market position.
- Evaluate the company's product pipeline and potential for future growth.
- Check for any legal or regulatory issues.
- Consult with a financial advisor before investing.
- Confirm the company's legitimacy and business operations.
- The company has a clear business model and revenue streams.
- Kuros Biosciences AG has an established presence in the biopharmaceutical industry.
- The company has a pipeline of products in development.
- The company has strategic partnerships and collaborations.
- The company has a management team with relevant experience.
CSBTF Healthcare Stock FAQ
What does the AI Score mean for CSBTF?
CSBTF holds an AI Score of 57/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Kuros Biosciences AG is a biopharmaceutical company focused on tissue repair and bone regeneration. Their pipeline includes orthobiologics and sealants, targeting orthopedics, spinal, dental, …
What does Kuros Biosciences AG do?
Kuros Biosciences AG is a biopharmaceutical company focused on developing and commercializing innovative products for tissue repair and bone regeneration. The company's portfolio includes orthobiologics, such as MagnetOs Granules and MagnetOs Putty, which are used in orthopedic, spinal, and dental procedures. Kuros Biosciences also develops fibrin/PTH orthobiologics and sealants, targeting unmet needs in orthopedic surgery and neurosurgery.
What are the main risks for CSBTF?
The main risks for Kuros Biosciences AG include the potential for unfavorable clinical trial results, delays in regulatory approval, and competition from other biopharmaceutical companies. The company's reliance on successful commercialization of existing products also poses a risk. Additionally, as an OTC-traded stock, CSBTF faces risks associated with limited financial disclosure, lower liquidity, and potential for increased price volatility. Investors should carefully consider these risks before investing in CSBTF.
What are the key factors to evaluate for CSBTF?
Kuros Biosciences AG (CSBTF) holds an AI score of 57/100 (moderate). Kuros Biosciences AG presents a compelling investment thesis based on its innovative product pipeline and strategic focus on tissue repair and bone regeneration. Not financial advice.
How frequently does CSBTF data refresh on this page?
CSBTF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CSBTF's recent stock price performance?
Kuros Biosciences AG (CSBTF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product pipeline targeting unmet clinical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CSBTF overvalued or undervalued right now?
Kuros Biosciences AG (CSBTF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CSBTF before investing?
Before investing in Kuros Biosciences AG (CSBTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CSBTF to a portfolio?
Key strength of Kuros Biosciences AG (CSBTF): Innovative product pipeline targeting unmet clinical needs. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis is pending for CSBTF, so some information may be incomplete.
- OTC market data may be less reliable than data for exchange-listed companies.